{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:51:38Z","timestamp":1780599098446,"version":"3.54.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Soonchunhyang University Research Fund and the National Research Foundation of Korea","award":["RS-2023-00251607"],"award-info":[{"award-number":["RS-2023-00251607"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and aims<\/jats:title>\n            <jats:p>Antiviral treatment (AVT) reduces hepatitis B virus (HBV) reactivation and hepatocsellular carcinoma (HCC) development; however, the impact of AVT timing \u2013 before versus after HCC diagnosis \u2013 on prognosis remains unclear. This study aimed to evaluate the current status, changes, and clinical outcomes of AVT before HCC diagnosis in Korea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data were extracted from the Korean National Health Insurance Service for patients newly diagnosed with HBV-related HCC from 2008 to 2018. Patients were categorized into an early cohort (2008\u20132013) and a late cohort (2014\u20132018). AVT trends were analyzed using Joinpoint regression, and clinical outcomes were compared between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 82 609 patients (early cohort: <jats:italic toggle=\"yes\">n<\/jats:italic> = 45 804; late cohort: <jats:italic toggle=\"yes\">n<\/jats:italic> = 36 805), the proportion receiving AVT before HCC diagnosis increased from 22.4% in 2008 to 46.8% in 2018. AVT after diagnosis also rose from 16.3 to 21.3%. Overall survival rates in the late cohort were significantly improved compared with the early cohort (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). More than half of the patients with HCC who received transplantation or local ablation treatment had received AVT before HCC diagnosis. AVT before HCC diagnosis was associated with reduced mortality rate (adjusted hazard ratio = 0.592; 95% confidence interval: 0.580\u20130.604; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Elderly patients (\u226580 years) consistently had a lower AVT rate before HCC diagnosis compared with other age groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The AVT rate before HCC diagnosis significantly increased over the past 10 years in Korea. Further efforts are needed to improve the AVT rate in elderly patients with HBV-related HCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000003000","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:02:14Z","timestamp":1752836534000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Changes in antiviral treatment rate for hepatitis B virus before hepatocellular carcinoma diagnosis: a nationwide Korean study"],"prefix":"10.1097","author":[{"given":"Young Eun","family":"Chon","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical and Digital Engineering, Hanyang University College of Engineering, Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen L.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Hanyang University, Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ajou University School of Medicine, Suwon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Bong","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Eulji University College of Medicine, Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung Won","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Hanyang University, Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"R1-20250903","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3904\/kjim.2019.007","article-title":"The epidemiology of hepatitis B virus infection in Korea.","volume":"34","author":"Yim","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"Suppl 1","key":"R3-20250903","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.","volume":"31","author":"Yin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-20250903","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"R6-20250903","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"R8-20250903","first-page":"5234969","article-title":"Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis.","volume":"2016","author":"Yuan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R9-20250903","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/v12080815","article-title":"Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead.","volume":"12","author":"Liu","year":"2020","journal-title":"Viruses"},{"key":"R10-20250903","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.29321","article-title":"Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population.","volume":"66","author":"Choi","year":"2017","journal-title":"Hepatology"},{"key":"R11-20250903","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.jhepr.2020.100152","article-title":"Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC.","volume":"2","author":"Hui","year":"2020","journal-title":"JHEP Rep"},{"key":"R12-20250903","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"R13-20250903","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3350\/cmh.2021.0395","article-title":"Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly.","volume":"29","author":"Chon","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R14-20250903","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R15-20250903","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R16-20250903","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B.","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R17-20250903","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C.","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R18-20250903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2017.0112","article-title":"Epidemiology of liver cancer in South Korea.","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"R19-20250903","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3350\/cmh.2021.0171","article-title":"Hepatocellular carcinoma statistics in South Korea.","volume":"27","author":"Chon","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R20-20250903","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: a systematic review.","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"R21-20250903","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection.","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"R22-20250903","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12072-007-9020-7","article-title":"Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.","volume":"2","author":"Yoshida","year":"2008","journal-title":"Hepatol Int"},{"key":"R23-20250903","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000003000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T16:03:54Z","timestamp":1756915434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000003000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000003000","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}